CUE$0.6152
$0.6194
Chart
Performance
Key Stats
AI CUE Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralCue Biopharma shows mixed signals. While the company operates in the promising biotech sector with potential for innovation, its current financial performance, characterized by consistent losses and negative net margins, coupled with a high beta, indicates significant risk. The stock's technicals are mixed across different timeframes. Investors should approach with caution and consider diversification.
Thematic
Cue Biopharma operates in the biopharmaceutical sector, which is inherently driven by innovation and the potential for disruptive therapies. Its focus on novel classes of injectable therapeutics targeting T cells for autoimmune diseases and cancer holds significant thematic appeal. However, the success of these therapies is highly dependent on clinical trial outcomes and regulatory approvals.
Fundamental
Cue Biopharma's fundamentals are currently weak, marked by significant operating losses, negative net income, and substantial negative net margins. While revenue has shown growth in recent periods, it is not yet translating into profitability. The company's substantial cash burn and negative free cash flow necessitate ongoing funding, posing a risk to long-term viability without further capital raises or successful product commercialization.
Technical
The stock exhibits mixed technical signals. While it has shown some recovery from its 52-week low, the price is still significantly below its 52-week high. Multiple indicators across various timeframes suggest a neutral to slightly bearish sentiment, with moving averages predominantly indicating 'Sell' signals. The high beta suggests volatility.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 80 |
| Targeted Therapies | 85 |
| Partnerships & Collaborations | 70 |
| Regulatory Landscape | 50 |
| Market Size & Potential | 75 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 65 |
| Balance Sheet Health | 60 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 55 |
| Volume Analysis | 50 |
| Support & Resistance | 45 |
| Volatility | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
EPS Surprise Trends
The company has exceeded EPS estimates in the last 3 consecutive quarters, with surprise percentages of 16.67%, 11.69%, and 11.35%.
Improving Cash Position
Cash equivalents have increased significantly from $10.05 million in Q4 2021 to $22.46 million in Q4 2024, demonstrating improved liquidity.
Bearish Points (8)
Negative Earnings Per Share (EPS)
The company has consistently reported negative EPS (e.g., -0.64 TTM), indicating it is not currently profitable on a per-share basis.
Significant Net Losses
The company has experienced substantial net losses, with Net Income at -40.67 million in 2024 and -50.73 million in 2023, resulting in deeply negative net margins.
Calendar
August 2025
13
Next Earnings Date
H: $-0.13
A: $-0.13
L: $-0.13
H: 2.00M
A: 2.00M
L: 2.00M
Profile
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer. It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Seasonals
Price Target
4.00 USD
The 39 analysts offering 1 year price forecasts for CUE have a max estimate of 6.00 and a min estimate of 2.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major competitor in point-of-care diagnostics (e.g., ID NOW platform) and broader medical devices, with a significant presence in infectious disease testing.
Weight: 90
Direct competitor in rapid diagnostic tests, particularly for infectious diseases like influenza and COVID-19, operating in the point-of-care space.
Weight: 88
Focuses on rapid diagnostics and point-of-care testing, including infectious diseases and consumer health, often with self-test capabilities.
Weight: 85
Specializes in point-of-care diagnostic tests for infectious diseases, often in resource-limited settings, representing a direct niche competitor.